05:20 AM EDT, 09/26/2024 (MT Newswires) -- Apimeds Pharmaceuticals on Wednesday filed regulatory papers for an initial public offering.

The date and pricing of the offering were not disclosed.

The company said it plans to trade on the New York Stock Exchange under the ticker symbol "APUS."

The company said Inscobee, a publicly traded company in South Korea, currently owns 88.8% of its common stock and will keep the majority of the voting power after the initial public offering.